Author

Stephen B. Rivers

Observed name: Stephen B Rivers

Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

Observed institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University of Ghana, Noguchi Memorial Institute for Medical Research

OpenAlex ID: A5000213618

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

2010 · K Zaman, Dang Duc Anh, et al. · The Lancet · 826

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

2010 · George E Armah, Samba O Sow, et al. · The Lancet · 657

Efficacy, Immunogenicity, and Safety of a Pentavalent Human-Bovine (WC3) Reassortant Rotavirus Vaccine at the End of Shelf Life

2007 · Stan L. Block, Timo Vesikari, et al. · PEDIATRICS · 137

Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa

2012 · Milagritos D. Tapia, George Armah, et al. · Vaccine · 43

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq®, in Kenya, including among HIV-infected and HIV-exposed infants

2012 · Kayla F. Laserson, Daveline Nyakundi, et al. · Vaccine · 32

Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh

2012 · K. Zaman, M. Yunus, et al. · Vaccine · 19

Works count: 6

Citation count: 1,714

H-index: 6

I10-index: 6